6533b85dfe1ef96bd12bea1f
RESEARCH PRODUCT
Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice.
Tania LópezJosé Manuel García-verdugoMaria Teresa RabenaGloria AbizandaMª Salomé Sirerol-piquerSilvia Mora-leeCatherine M. VerfaillieMayte Casado-nietoFelipe ProsperMaría Gutiérrez-pérezUlises Gómez-pinedoValerie D. Roobroucksubject
MaleAnatomy and PhysiologyMousemedicine.medical_treatmentCell therapyMiceCell MovementMolecular Cell BiologyNeurobiology of Disease and RegenerationMedicineMultidisciplinaryNeuronal MorphologyNeurogenesisQRBrainInfarction Middle Cerebral ArteryAnimal ModelsStem-cell therapyStrokeAdult Stem Cellsmedicine.anatomical_structureNeurologyMedicineResearch ArticleAdult stem cellCell PhysiologyHistologyCell SurvivalCerebrovascular DiseasesScienceTherapeutic effectsNeurophysiologyNeovascularization PhysiologicSubventricular zoneMesenchymal Stem Cell TransplantationNeurological SystemModel OrganismsAnimalsHumansProgenitor cellBiologyTransplantationbusiness.industryMultipotent Stem CellsMesenchymal stem cellMultipotent Stem CellCellular NeuroscienceImmunologyCancer researchMolecular NeurosciencebusinesshMAPC and hMSCNeurosciencedescription
Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2(-/-) γC(-/-) mice subjected to FeCl(3) thrombosis mediated stroke were intracranially injected with 2 × 10(5) hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison with PBS-treated animals, hMSC and hMAPC grafted animals demonstrated significantly decreased loss of brain tissue. This was associated with increased angiogenesis, diminished inflammation and a glial-scar inhibitory effect. Moreover, enhanced proliferation of cells in the subventricular zone (SVZ) and survival of newly generated neuroblasts was observed. Interestingly, these neuroprotective effects were more pronounced in the group of animals treated with hMAPCs in comparison with hMSCs. Our results establish cell therapy with hMAPCs and hMSCs as a promising strategy for the treatment of stroke. ispartof: PLoS One vol:7 issue:8 ispartof: location:United States status: published
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-01-01 | PLoS ONE |